Abera Bioscience AB is a Sweden-based company, which is active in biotechnology. Abera Bioscience is platform and vaccine development company active in the medical, molecular and microbiological field. The Companyâ€™s purpose is to develop vaccine candidates based on its vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and immunooncology. The business is located around the Nordic market.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	SEK 8.100	0.00%	800
03/09/26	SEK 8.100	0.00%	1,634
02/09/26	SEK 8.100	+2.53%	86
01/09/26	SEK 7.900	-0.75%	4,678
31/08/26	SEK 7.960	-2.21%	338

End-of-day quote NORDIC GROWTH MARKET

More quotes

Net sales - Rate of surprise

Company calendar

End-of-day quote NORDIC GROWTH MARKET 03/09/2026			5-day change	1st Jan Change
8.100 ^SEK	0.00%		-0.74%	+19.12%

08-20	Abera Bioscience widens operating loss, 'working intensively to broaden the pipeline', CEO says	FW
08-20	Abera Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	166M 17.36M 14.93M 14.05M 12.84M 24.01M 1.64B 24.08M 64.43M 841M 65.17M 63.75M 2.71B	P/E 2024	-64.4x	P/E 2025	-10.8x
Enterprise Value	143M 14.9M 12.82M 12.06M 11.02M 20.62M 1.41B 20.67M 55.32M 722M 55.95M 54.73M 2.33B	EV / Sales 2024	4.32x	EV / Sales 2025	8.6x
Free-Float	40.83%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
NORDIC GROWTH MARKET	ABERA	End-of-day quote
Deutsche Boerse AG	8WK	Delayed
Deutsche Boerse AG	8WK	End-of-day quote

08-20	Abera Bioscience widens operating loss, 'working intensively to broaden the pipeline', CEO says	FW
08-20	Abera Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Abera Bioscience raises SEK 7.9m after warrant exercise	FW
07-22	Abera Bioscience applies to begin Phase I study of vaccine candidate	FW
07-20	Abera Biosciences management and staff buy stock options from board member	FW
06-30	Abera Bioscience reports results from ferret study	FW
06-16	CEPI extends support for Abera vaccine project	FW
06-08	Abera Bioscience completes production ahead of clinical trial for vaccine candidate	FW
05-12	Abera Bioscience reports operating loss in Q1	FW
05-12	Abera Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Abera Bioscience vaccine technology bolstered by scientific publication	FW
02-12	Abera Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-12	Abera Bioscience Swings to Operating Loss, 'Vaccine Candidate Development Continues as Planned' - CEO	FW

Abera Bioscience AB Stock

Stocks

ABERA

SE0015245097

Biotechnology & Medical Research

Valuation : Abera Bioscience AB

Chart: Abera Bioscience AB

Latest news : Abera Bioscience AB

Analysts' recommendations : Abera Bioscience AB

Press Releases : Abera Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors : Abera Bioscience AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

30/08/24	Carlsquare lowers motivated value for Abera Bioscience	FW
23/05/24	Carlsquare lowers the motivated value for Abera Bioscience	FW
16/11/23	Carlsquare raises motivated value for Abera Bioscience slightly to SEK 11.80	FW

1 week	-0.74%
Current month	+1.76%
1 month	+1.00%
3 months	+19.47%
6 months	+29.60%
Current year	+19.12%

1 week	7.52	8.14
1 month	7.52	8.94
Current year	5.15	10.05
1 year	5.15	10.05
3 years	3.24	10.05
5 years	3.05	30.8
10 years	3.05	30.8

Manager	Title	Age	Since
Maria Alriksson CEO	Chief Executive Officer	43	01/10/2020
Joen Luirink CTO	Chief Tech/Sci/R&D Officer	66	03/11/2012
Mats Fredrik Lundgren CTO	Chief Tech/Sci/R&D Officer	61	01/05/2022

Director	Title	Age	Since
Leif Anders Gunnar Ericsson CHM	Chairman	56	01/01/2015
Fredrik Juserius BRD	Director/Board Member	59	01/01/2020
Ulla Cristina Glad BRD	Director/Board Member	74	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABERA BIOSCIENCE AB	0.00%	-0.74%	-2.41%	+100.99%	17.38M
LONZA GROUP AG	-2.54%	-3.60%	-0.60%	+15.17%	50.35B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+439.20%	+523.39%	45.2B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+45.46%	+21.22%	44.71B
BEONE MEDICINES AG	-1.22%	-2.31%	+12.40%	+74.90%	41.24B
CELLTRION, INC.	+0.53%	-1.67%	+15.16%	+49.88%	33.08B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.81B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+22.59%	+123.04%	16.56B
EUROFINS SCIENTIFIC SE	-1.01%	-0.38%	+15.69%	+28.39%	14.82B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+77.75%	+41.22%	14B
Average	-1.03%	-0.04%	+69.47%	+108.69%	27.78B
Weighted average by Cap.	-1.38%	-0.46%	+94.48%	+127.49%

	2024	2025
Net sales	14.63M 1.53M 1.32M 1.24M 1.13M 2.12M 144M 2.12M 5.68M 74.07M 5.74M 5.62M 239M	11.85M 1.24M 1.07M 1M 916K 1.71M 117M 1.72M 4.6M 60.01M 4.65M 4.55M 193M
Net income	-1.1M -115K -98.94K -93.09K -85.04K -159K -10.86M -160K -427K -5.57M -432K -422K -17.94M	-10.45M -1.09M -940K -885K -808K -1.51M -103M -1.52M -4.06M -52.93M -4.1M -4.01M -171M
Net Debt	-6.09M -637K -548K -515K -471K -881K -60.1M -883K -2.36M -30.84M -2.39M -2.34M -99.34M	-23.49M -2.46M -2.11M -1.99M -1.82M -3.4M -232M -3.41M -9.11M -119M -9.22M -9.02M -383M